Fundamental Analysis of ADMA Biologics Inc - Growth / Value Index
ADMA - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 12.50
Price to Book Ratio of 14.39 suggesting that it is very expensive
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -572.29 | -88899.55 | -422311.03 % | |
| Price to Book | 14.23 | 15008.46 | 127129 % | 13.94 |
| Price to Sales | 7.36 | 8661.11 | 74338.88 % | |
| Enterprise Value to EBITDA Multiple | 93.94 | 205336 | 517608 % |
ADMA - Profitability Highlights
Profitability Analysis
Annual Net Profit in last 3 years is trending up
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
EBITDA is continuously increasing for last 3 Years
Steady Growth in EPS for last four quarters
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -2.49 | -16.88 | 69.88 % | 11.58 |
| Return On Asset | -1.06 | -6.93 | 71.63 % | 5.07 |
| Net Profit Margin | -1.29 | -9.74 | 82.38 % | 21.75 |
| Operating Profit Margin | 15.63 | 0.572 | 101.89 % | 26.65 |
| EBITDA Margin | 8.20 | 4.22 | 113.94 % | 26.65 |
Highlights
| Market Cap | 2100.19 M |
| Enterprise Value | 2180.48 M |
| Price/Book TTM | 14.23 |
| Outstanding Share | 231808 K |
| Float/ Outstanding Share | 98.01% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 3.00 |
| Altman Z Score | 5.83 |
| Sloan Ratio | -0.0202 |
| Peter Lynch Fair Value | 0 |
ADMA - Growth Highlights
Growth Analysis
Short term positive trend in total sale and net profit
STRONG JUMP IN NET SALE : YoY growth
Tremendous increasing trend in total sale last 3 year
Quarterly sales in last 5 years is trending up
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 283176 K | 52.06 % | 10.79 % |
| Gross Profit | 111537 K | 104.26 % | 25.80 % |
| EBITDA | 23211.41 K | 121.20 % | 334.11 % |
| Net Profit | -3644.18 K | 73.20 % | 200.92 % |
| EPS | -0.0158 | 99.98 % | NA |
ADMA - Stability Highlights
Stability Analysis
Altman Z Score of 5.90 suggests good Stability
Decreasing debt with Increasing revenue
Tsr Stability Index - Poor Score of 31.25
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0.070
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.974 | 2.94 % | 0.858 |
| Cash Ratio | 1.03 | -53.21 % | |
| Quick Ratio | 1.69 | -38.10 % | 1.86 |
| Shareholders Equity | 41.07 | -5.82 % | |
| Debt to EBITDA | 13.32 | 532.06 % |
Historical Valuation Ratios of ADMA Biologics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of ADMA Biologics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of ADMA Biologics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of ADMA Biologics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)